Study guide
21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections
Key Takeaways Explain This Topic AI
Beta-lactams show time-dependent killing (efficacy depends on the time free drug concentration stays above the MIC), whereas aminoglycosides show concentration-dependent killing with a post-antibiotic effect, so they are given once daily.
Critically ill patients may need higher loading doses of hydrophilic antibiotics because of an increased volume of distribution, and augmented renal clearance can cause subtherapeutic beta-lactam levels.
Antimicrobial stewardship means taking cultures before antibiotics when possible, choosing appropriate empirical cover, reviewing at 48-72 hours, de-escalating to the narrowest effective agent and using the shortest effective duration.
Ventilator-associated pneumonia occurs after at least 48 hours of mechanical ventilation; prevention includes head-up positioning, daily sedation interruption, subglottic secretion drainage and minimising ventilation duration.
Catheter-related bloodstream infection is reduced by insertion bundles (hand hygiene, full barrier precautions, chlorhexidine-alcohol skin preparation, avoiding the femoral site where possible) and prompt removal of unnecessary catheters.
Last updated: October 2026
- 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections
- Antibiotic Classes and Mechanisms
Class Examples Mechanism Key points
Penicillins Amoxicillin, piperacillin-tazobactam, flucloxacillin Inhibit cell wall synthesis (bind penicillin-binding proteins) Time-dependent; beta-lactamase inhibitors extend spectrum
Cephalosporins Cefazolin, ceftriaxone, ceftazidime As penicillins Cross-reactivity with penicillin allergy is low (about 1-2%), mainly with similar side chains
Carbapenems Meropenem As penicillins; stable to most beta-lactamases Reserve for resistant Gram-negatives (ESBL producers); lower seizure threshold (imipenem)
Glycopeptides Vancomycin, teicoplanin Inhibit cell wall synthesis (Gram-positive only) Vancomycin: infuse slowly (flushing reaction); monitor levels; nephrotoxic
Aminoglycosides Gentamicin, amikacin Inhibit 30S ribosome Concentration-dependent; nephrotoxic and ototoxic; potentiate neuromuscular block
Macrolides Clarithromycin, azithromycin Inhibit 50S ribosome QT prolongation; CYP3A4 inhibition (clarithromycin)
Fluoroquinolones Ciprofloxacin, levofloxacin Inhibit DNA gyrase QT prolongation, tendon rupture, seizures, aortic aneurysm risk
- Lincosamides Clindamycin 50S ribosome Toxin suppression in necrotising infection; C. difficile risk
- Oxazolidinones Linezolid 50S ribosome MRSA and VRE; serotonin syndrome with SSRIs; thrombocytopenia
- Nitroimidazoles Metronidazole DNA damage in anaerobes Disulfiram-like reaction; potentiates warfarin
- Polymyxins Colistin Disrupt cell membrane Last-line for carbapenem-resistant Gram-negatives; nephrotoxic
- Pharmacokinetics and Pharmacodynamics in Critical Illness
- Killing Patterns
Pattern Target Examples Dosing strategy
Time-dependent Time free drug concentration exceeds the minimum inhibitory concentration ( f T > MIC fT > \text{MIC} f T > MIC ) Beta-lactams Frequent doses or extended/continuous infusions
Concentration-dependent Peak concentration to MIC ratio ( C m a x / MIC C_{max}/\text{MIC} C ma x / MIC ) Aminoglycosides Large once-daily doses (also reduces toxicity)
Exposure-dependent Area under the curve to MIC ratio (AUC/MIC) Vancomycin, fluoroquinolones Dose to AUC targets; therapeutic drug monitoring
Altered Handling in the Critically Ill
Increased volume of distribution (capillary leak, fluid resuscitation) lowers concentrations of hydrophilic drugs (beta-lactams, aminoglycosides, vancomycin), so loading doses should not be reduced even in renal impairment.
Augmented renal clearance (creatinine clearance above about 130 mL/min, common in young trauma, sepsis and head injury patients) causes subtherapeutic beta-lactam levels.
Renal replacement therapy and ECMO alter clearance and sequestration; therapeutic drug monitoring helps.
Hypoalbuminaemia increases the free fraction and clearance of highly protein-bound drugs such as ceftriaxone and teicoplanin.
Antimicrobial Stewardship
The aims are to improve outcomes, reduce toxicity and limit resistance.
Take cultures before antibiotics when this does not cause a significant delay (blood cultures, relevant sites).
Give appropriate empirical therapy promptly in sepsis and septic shock, based on local resistance patterns, the likely source, and risk factors for resistant organisms.
Review at 48-72 hours with culture results: stop, de-escalate to a narrower agent, switch to oral, or continue.
Shortest effective duration: for many infections 5-7 days is enough once source control has been achieved (for example intra-abdominal infection after source control, uncomplicated pneumonia).
Procalcitonin can support decisions to stop antibiotics, but it should not delay starting them in suspected sepsis.
Source control (drainage, debridement, removal of infected devices) is as important as antibiotic choice.
Multidrug-Resistant Organisms
Organism Resistance mechanism Treatment options
MRSA Altered penicillin-binding protein (PBP2a, mecA gene) Vancomycin, teicoplanin, linezolid, daptomycin (not for pneumonia)
- VRE Altered cell wall target Linezolid, daptomycin
- ESBL-producing Enterobacterales Extended-spectrum beta-lactamases Carbapenems
Carbapenemase producers (CPE), e.g. KPC, NDM, OXA-48 Carbapenem-hydrolysing enzymes Newer combinations (for example ceftazidime-avibactam for KPC and OXA-48), colistin, specialist advice
Pseudomonas aeruginosa Efflux pumps, porin loss, beta-lactamases Anti-pseudomonal beta-lactam (piperacillin-tazobactam, ceftazidime, meropenem), guided by susceptibility
Infection prevention (hand hygiene, contact precautions, screening and cohorting) is essential to limit spread.
- ICU-Acquired Infections
- Ventilator-Associated Pneumonia (VAP)
Definition: pneumonia developing after at least 48 hours of invasive mechanical ventilation . Diagnosis combines new or progressive infiltrates, fever or leucocytosis, purulent secretions and worsening oxygenation, ideally with quantitative cultures from lower respiratory samples.
Prevention bundle:
Head of the bed elevated 30-45° .
Daily sedation interruption and spontaneous breathing trials to shorten ventilation.
Subglottic secretion drainage tubes and appropriate cuff pressure (about 20-30 cmH2O).
Oral care (routine chlorhexidine mouthwash is now debated because of possible harm).
Avoid unplanned extubation and re-intubation; use non-invasive ventilation where appropriate.
Treatment: empirical cover based on local resistance and risk factors (early-onset VAP within about 4 days is more often caused by community organisms; late-onset by resistant hospital organisms), de-escalated with cultures; a 7-day course is usually sufficient.
Catheter-Related Bloodstream Infection (CRBSI)
Diagnosed by matching organisms in peripheral and catheter blood cultures, with earlier positivity of the catheter culture (differential time to positivity of 2 hours or more) or catheter tip culture.
Prevention (insertion bundle): hand hygiene, full sterile barrier precautions, 2% chlorhexidine in 70% alcohol skin preparation, ultrasound guidance, avoiding the femoral site in adults where possible, and daily review.
Treatment: remove the catheter in most cases (always for Staphylococcus aureus and Candida ), and give appropriate antibiotics (at least 14 days for S. aureus bacteraemia, with echocardiography to exclude endocarditis).
Clostridioides difficile Infection
Risk factors: broad-spectrum antibiotics (clindamycin, cephalosporins, fluoroquinolones), proton pump inhibitors, age and hospital stay. Treat with oral vancomycin or fidaxomicin , stop unnecessary antibiotics, use contact precautions, and wash hands with soap and water (alcohol gel does not kill spores). Severe disease can cause toxic megacolon.
Fungal Infection
Invasive candidiasis risk factors include broad-spectrum antibiotics, central venous catheters, parenteral nutrition, abdominal surgery and renal replacement therapy. Echinocandins (for example caspofungin) are first-line for invasive candidiasis in critically ill patients.